Table 5 Tumour responses according to histologic type (N=56)

From: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

  Small-cell carcinoma Nonsmall-cell carcinoma
Response N (%) N (%)
Complete response 2 (18) 0 (0)  
Partial response 8 (73) 17 (38)
No change 0 (0) 18 (40)
Progressive disease 0 (0) 8 (18)
Not evaluable 1 (9) 2 (4)